ATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies Consortium

The National Institute on Aging – Alzheimer's Association (NIA‐AA) ATN research framework proposes to use biomarkers for amyloid (A), tau (T), and neurodegeneration (N) to stage individuals with AD pathological features and track changes longitudinally. The overall aim was to utilize this framework to characterize pre‐mortem ATN status longitudinally in a clinically diagnosed cohort of dementia with Lewy bodies (DLB) and to correlate it with the post mortem diagnosis.

[1]  W. M. van der Flier,et al.  Longitudinal change in ATN biomarkers in cognitively normal individuals , 2022, Alzheimer's research & therapy.

[2]  W. M. van der Flier,et al.  Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies , 2022, Neurology.

[3]  D. V. Rosa,et al.  Millipore xMap® Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer's Biomarkers in Cerebrospinal Fluid , 2021, Frontiers in Psychiatry.

[4]  K. Blennow,et al.  Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[5]  G. Piñol-Ripoll,et al.  Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest , 2021, Frontiers in Aging Neuroscience.

[6]  K. Blennow,et al.  Effects of amyloid pathology and the APOE ε4 allele on the association between cerebrospinal fluid Aβ38 and Aβ40 and brain morphology in cognitively normal 70-years-olds , 2021, Neurobiology of Aging.

[7]  B. Boeve,et al.  Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group , 2021, Alzheimer's & dementia.

[8]  M. Eckerström,et al.  Evaluation of the ATN model in a longitudinal memory clinic sample with different underlying disorders , 2021, Alzheimer's & dementia.

[9]  James G. Bollinger,et al.  The global Alzheimer's Association round robin study on plasma amyloid β methods , 2021, Alzheimer's & dementia.

[10]  L. Parnetti,et al.  A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies , 2020, Diagnostics.

[11]  Jun Pyo Kim,et al.  Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum , 2020, Journal of Korean medical science.

[12]  H. Feldman,et al.  Applying the Alzheimer Disease ATN Diagnostic Framework in Atypical Dementia. , 2020, Alzheimer disease and associated disorders.

[13]  K. Blennow,et al.  Comparative Analysis of Different Definitions of Amyloid-β Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer , 2020, The Journal of Prevention of Alzheimer's Disease.

[14]  W. M. van der Flier,et al.  ATN classification and clinical progression in subjective cognitive decline , 2020, Neurology.

[15]  O. Hansson,et al.  The implications of different approaches to define AT(N) in Alzheimer disease , 2020, Neurology.

[16]  H. Houlden,et al.  Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review , 2020, Journal of the Neurological Sciences.

[17]  Y. Guan,et al.  Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study , 2020, The Journal of Nuclear Medicine.

[18]  L. Parnetti,et al.  Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ? , 2020, Alzheimer's research & therapy.

[19]  L. Tan,et al.  Discordant Alzheimer's neurodegenerative biomarkers and their clinical outcomes , 2020, Annals of clinical and translational neurology.

[20]  Gerrit Hirschfeld,et al.  cutpointr: Improved Estimation and Validation of Optimal Cutpoints in R , 2020, J. Stat. Softw..

[21]  C. Jack,et al.  Association of Longitudinal β-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia , 2019, JAMA network open.

[22]  Kohske Takahashi,et al.  Welcome to the Tidyverse , 2019, J. Open Source Softw..

[23]  R. Irizarry.  ggplot2 , 2019, Introduction to Data Science.

[24]  B. Ghetti,et al.  α‐Synuclein RT‐QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies , 2019, Annals of clinical and translational neurology.

[25]  K. Blennow,et al.  Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. , 2019, Clinical biochemistry.

[26]  J. Attems,et al.  Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies – current issues and future directions , 2019, Journal of neurochemistry.

[27]  H. Zetterberg.  THE GLOBAL ALZHEIMER’S ASSOCIATION ROUND ROBIN STUDY ON PLASMA AMYLOID BETA METHODS , 2019, Alzheimer's & Dementia.

[28]  G. Qin,et al.  Partial Youden index and its inferences , 2018, Journal of biopharmaceutical statistics.

[29]  F. Blanc,et al.  Diagnostic value of Alzheimer's biomarkers in cerebrospinal fluid in dementia with Lewy body. , 2018, Geriatrie et psychologie neuropsychiatrie du vieillissement.

[30]  Yue Huang,et al.  Reader response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium , 2018, Neurology.

[31]  D. Y. Lee,et al.  Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease , 2017, Alzheimer's & Dementia.

[32]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[33]  E. Londos,et al.  Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia , 2016, Movement disorders : official journal of the Movement Disorder Society.

[34]  Harald Hampel,et al.  Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. , 2015, Brain : a journal of neurology.

[35]  Carmen Cadarso-Suárez,et al.  OptimalCutpoints: An R Package for Selecting Optimal Cutpoints in Diagnostic Tests , 2014 .

[36]  Eric Westman,et al.  Meta-Review of CSF Core Biomarkers in Alzheimer’s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria , 2014, Front. Aging Neurosci..

[37]  Yixin Fang,et al.  A model‐free estimation for the covariate‐adjusted Youden index and its associated cut‐point , 2014, Statistics in medicine.

[38]  Benjamin Reiser,et al.  Construction of confidence regions in the ROC space after the estimation of the optimal Youden index‐based cut‐off point , 2013, Biometrics.

[39]  R. Barker,et al.  Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines , 2012, Movement disorders : official journal of the Movement Disorder Society.

[40]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[41]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[42]  Marcus D. Ruopp,et al.  Youden Index and Optimal Cut‐Point Estimated from Observations Affected by a Lower Limit of Detection , 2008, Biometrical journal. Biometrische Zeitschrift.

[43]  B. Ravina,et al.  The montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[44]  I. McKeith,et al.  Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study , 2007, The Lancet Neurology.

[45]  H. Engler,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[46]  A. Pfeufer,et al.  TaqMan Systems for Genotyping of Disease-Related Polymorphisms Present in the Gene Encoding Apolipoprotein E , 2002, Clinical chemistry and laboratory medicine.

[47]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[48]  G. Schellenberg,et al.  Clinicopathologic correlations of soluble amyloid beta-protein precursor in cerebrospinal fluid in patients with Alzheimer disease and controls. , 1997, Alzheimer disease and associated disorders.

[49]  H. Braak,et al.  Staging of alzheimer's disease-related neurofibrillary changes , 1995, Neurobiology of Aging.

[50]  C. Lippa,et al.  Alzheimer's disease and Lewy body disease: A comparative clinicopathological study , 1994, Annals of neurology.

[51]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[52]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[53]  W. Yarberry.  DPLYR , 2021, CRAN Recipes.

[54]  A. Thomas,et al.  Amyloid PET Imaging in Lewy body disorders. , 2015, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.